Literature DB >> 17360238

Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy.

Hanlu Ding1, Yani He, Kailong Li, Jurong Yang, Xiaolin Li, Rong Lu, Wenda Gao.   

Abstract

Renal tubulointerstitial injury plays an important role in the development of IgA nephropathy (IgAN), the most common form of glomerulonephritis. Few currently in use biomarkers can sensitively detect the earliest signs of renal tubular injury, hindering our efforts to launch preventive and therapeutic measures for this disorder in a timely manner. Neutrophil gelatinase-associated lipocalin (NGAL) is an acute phase protein that is rapidly released from not only neutrophils but also a variety of cell types upon inflammation and tissue injury. Its small molecular size and protease resistance could render it an excellent biomarker of renal injury in IgAN. In this study, we tested this hypothesis by measuring urinary levels of NGAL, creatinine and N-acetyl-beta-D-glucosaminidase (NAG) in 40 healthy individuals and 70 IgAN patients with various disease severities. The urinary NGAL levels and NGAL/creatinine values were significantly upregulated in Lee grade III IgAN patients, in correlation with progressive glomerular mesangial proliferation and tubulointerstitial injury. Compared with urinary NAG levels, the urinary NGAL levels elevated much more drastically and can be readily detected even in Lee grade II IgAN patients when their NAG levels showed almost no change. Our findings suggest the promising use of urinary NGAL as an early biomarker for tubulointerstitial injury of IgA nephropathy and perhaps other types of renal disease in general.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360238     DOI: 10.1016/j.clim.2007.01.010

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  66 in total

1.  Lipocalin 2 is essential for chronic kidney disease progression in mice and humans.

Authors:  Amandine Viau; Khalil El Karoui; Denise Laouari; Martine Burtin; Clément Nguyen; Kiyoshi Mori; Evangéline Pillebout; Thorsten Berger; Tak Wah Mak; Bertrand Knebelmann; Gérard Friedlander; Jonathan Barasch; Fabiola Terzi
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

Review 2.  Biomarkers in chronic kidney disease, from kidney function to kidney damage.

Authors:  Salvador Lopez-Giacoman; Magdalena Madero
Journal:  World J Nephrol       Date:  2015-02-06

Review 3.  The use of targeted biomarkers for chronic kidney disease.

Authors:  Prasad Devarajan
Journal:  Adv Chronic Kidney Dis       Date:  2010-11       Impact factor: 3.620

Review 4.  Neutrophil gelatinase-associated lipocalin--an emerging troponin for kidney injury.

Authors:  Prasad Devarajan
Journal:  Nephrol Dial Transplant       Date:  2008-09-22       Impact factor: 5.992

5.  Emerging urinary biomarkers in the diagnosis of acute kidney injury.

Authors:  Prasad Devarajan
Journal:  Expert Opin Med Diagn       Date:  2008-04

Review 6.  Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development.

Authors:  Leonie van Meer; Matthijs Moerland; Adam F Cohen; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

7.  Roles of neutrophil gelatinase-associated lipocalin in continuous ambulatory peritoneal dialysis-related peritonitis.

Authors:  Joseph C K Leung; Man Fai Lam; Sydney C W Tang; Loretta Y Y Chan; K Y Tam; Terence P S Yip; Kar Neng Lai
Journal:  J Clin Immunol       Date:  2009-01-16       Impact factor: 8.317

Review 8.  Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease.

Authors:  Prasad Devarajan
Journal:  Scand J Clin Lab Invest Suppl       Date:  2008

Review 9.  Progression from acute kidney injury to chronic kidney disease: a pediatric perspective.

Authors:  Stuart L Goldstein; Prasad Devarajan
Journal:  Adv Chronic Kidney Dis       Date:  2008-07       Impact factor: 3.620

10.  Urine NGAL and KIM-1 in children and adolescents with hyperuricemia.

Authors:  Justyna Tomczak; Anna Wasilewska; Robert Milewski
Journal:  Pediatr Nephrol       Date:  2013-05-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.